Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional MRI in Pancreatic Neuroendocrine Tumors and Comparison with 68Ga-DOTANOC PET/CT Abstract #987

Introduction: Pancreatic neuroendocrine tumors (pNETs) are often difficult to detect because of small size and have variable prognosis related to grading and staging.
Aim(s): To investigate the added value of DWI in pNETs evaluation and to compare MRI results with those of 68GaDOTANOC PET/CT.
Materials and methods: MRI (morphological/DWI) and 68GaDOTANOC PET/CT in 25 patients/30 pNETs were retrospectively evaluated. Per-patient and per-lesion detection rates (pDR, lDR) were calculated. ADC values were compared among: - pNET, surrounding and normal pancreas (control group); - tumors different grading and staging groups.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Maria Gabriella Brizi

To read results and conclusion, please login ...

Further abstracts you may be interested in

#589 Pancreatic neuroendocrine tumors and Diffusion weighted MRI: a better tool for detection?
Introduction: Pancreatic neuroendocrine tumors (pNETs) are often difficult to detect because of small size. Because surgery is curative in localized pNETs, preoperative localization is necessary.
Conference:
Category: Clinical
Presenting Author: Miss Alessandra Farchione
#2777 Tumor-to-Liver Ratio of Ga-68-DOTATOC PET/CT as a Prognostic Parameter in Metastatic, Well-Differentiated Gastroenteropancreatic-Neuroendocrine Tumor Patients Who Received Lanreotide Therapy
Introduction: Lanreotide is a long-acting somatostatin analogue with proven antitumor effect against metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors (GEP-NETs). Ga-68-DOTATOC PET/CT is a sensitive imaging technique for NETs by targeting somatostatin receptors.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Yong-Il Kim
Authors: Kim Y I, Yoo C, Ryoo B Y, Ryu J S, ...
#2882 Impact of Ga68-DOTATOC PET/MRI on Therapy Management in Patients with Neuroendocrine Neoplasia (NEN) - Preliminary Results
Introduction: Integrated PET/MRI combines the sensitivity and functional relevance of PET imaging and the spatial resolution and soft tissue contrast of MRI.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. med. Piotr Radojewski
#2947 Al18F-NOTA-Octreotide PET Imaging of the Somatostatin Receptor: First Comparison with 68Ga-DOTATATE in Neuroendocrine Tumor Patients
Introduction: Practical and economic challenges limit the widespread use of 68Ga-labeled somatostatin analog (SSA) PET, the current standard for somatostatin receptor imaging. A promising 18F-labeled SSA, Al18F-NOTA-octreotide (Al18F-OC), has recently been introduced.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Elin Pauwels
#2959 Synergic Value of 68Ga-DOTATOC PET and MRI in NET Patients Undergoing Simultaneous 68Ga-DOTATOC PET/MRI Scan
Introduction: The simultaneous acquisition of 68Ga-DOTATOC PET and functional MRI has relevant implication in the field of Neuroendocrine Tumours (NETs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD Paola Mapelli